Live price temporarily unavailable.
Prelude Therapeutics (PRLD) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | — | — | $7.00M | $12.1M |
| Growth (year over year) | — | — | — | — | — | — | +73.4% |
| Operating income | −$28.1M | −$58.8M | −$113.7M | −$123.5M | −$132.3M | −$139.7M | −$104.6M |
| Operating margin | — | — | — | — | — | −1995.9% | −861.3% |
| Net income | −$27.6M | −$56.9M | −$111.7M | −$115.4M | −$121.8M | −$127.2M | −$99.5M |
| Net margin | — | — | — | — | — | −1816.8% | −819.6% |
| EPS (diluted) | −$16.52 | −$4.56 | −$2.43 | −$2.44 | −$2.02 | −$1.68 | −$1.29 |
| Balance sheet | |||||||
| Cash and equivalents | $18.9M | $218.3M | $31.8M | $30.6M | $25.3M | $12.5M | $35.3M |
| Total assets | $21.9M | $223.6M | $305.1M | $220.5M | $277.7M | $175.5M | $141.3M |
| Total liabilities | $4.84M | $11.4M | $19.2M | $25.1M | $40.6M | $44.1M | $72.7M |
| Shareholders' equity | −$49.4M | $212.2M | $285.9M | $195.4M | $237.1M | $131.5M | $68.6M |
| Cash flow | |||||||
| Operating cash flow | −$25.7M | −$46.2M | −$83.5M | −$83.7M | −$107.1M | −$102.9M | −$56.3M |
| Capital expenditure | $780.0K | $621.0K | $2.32M | $3.02M | $3.51M | $764.0K | $67.0K |
| Free cash flow | −$26.4M | −$46.8M | −$85.9M | −$86.7M | −$110.6M | −$103.7M | −$56.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.00M | $4.00M | $0 | $0 | $6.50M | — | $4.58M | $5.70M |
| Growth (year over year) | — | — | — | — | +116.7% | — | — | — |
| Operating income | −$34.4M | −$33.8M | −$34.6M | −$32.2M | −$20.4M | — | −$14.2M | −$15.5M |
| Operating margin | −1145.9% | −845.8% | — | — | −314.1% | — | −309.5% | −270.9% |
| Net income | −$32.3M | −$28.7M | −$32.1M | −$31.2M | −$19.7M | — | −$10.4M | −$13.9M |
| Net margin | −1075.7% | −718.3% | — | — | −303.5% | — | −226.7% | −244.1% |
| EPS (diluted) | −$0.43 | −$0.37 | −$0.42 | −$0.41 | −$0.26 | — | −$0.13 | −$0.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $11.1M | $12.5M | $40.3M | $25.8M | $47.5M | $35.3M | $21.8M | $26.3M |
| Total assets | $197.2M | $175.5M | $141.3M | $114.9M | $94.8M | $141.3M | $119.6M | $189.4M |
| Total liabilities | $40.8M | $44.1M | $38.1M | $39.1M | $36.2M | $72.7M | $59.5M | $55.6M |
| Shareholders' equity | $156.4M | $131.5M | $103.2M | $75.8M | $58.5M | $68.6M | $60.2M | $133.7M |
| Cash flow | ||||||||
| Operating cash flow | −$27.3M | −$20.7M | −$34.2M | −$26.1M | −$19.1M | — | −$21.7M | −$15.6M |
| Capital expenditure | $63.0K | $53.0K | $47.0K | $20.0K | $0 | — | $0 | $0 |
| Free cash flow | −$27.4M | −$20.8M | −$34.3M | −$26.1M | −$19.1M | — | −$21.7M | −$15.6M |
From Prelude Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Prelude Therapeutics in our feed yet.